I. Requirements for Prior Authorization of Antipsychotics

A. Prescriptions That Require Prior Authorization

Prescriptions for Antipsychotics that meet any of the following conditions must be prior authorized:

1. A prescription for a non-preferred Antipsychotic, regardless of the quantity prescribed. See Preferred Drug List (PDL) for the list of preferred Antipsychotics at:

2. A prescription for a preferred Antipsychotic with a prescribed quantity that exceeds the quantity limit. See Quantity Limits for the list of drugs with quantity limits at:
   http://www.dpw.state.pa.us/ucmprd/groups/webcontent/documents/document/s_002077.pdf

3. A prescription for either a preferred or non-preferred Antipsychotic regardless of quantity limit when prescribed for a child under 18 years of age.

4. A prescription for an Atypical Antipsychotic when there is a record of a recent paid claim for another Atypical Antipsychotic in the Department’s Point-of-Sale On-Line Claims Adjudication System, (therapeutic duplication)

GRANDFATHER PROVISION – The Department will grandfather prescriptions for non-preferred Antipsychotics for those recipients age 18 years and older when the PROMISee Point-Of-Sale On-Line Claims Adjudication System verifies that the recipient has a record of a paid claim for a non-preferred Antipsychotic within the past 90 days from the date of service of the new claim. If the recipient has a record of a paid claim for a non-preferred Antipsychotic, a prescription or a refill for the same non-preferred Antipsychotic will be automatically approved.

Grandfathering does not apply to children under 18 years of age when prescribed either a preferred or non-preferred Antipsychotic or to prescriptions for Atypical Antipsychotics that are therapeutic duplications.

B. Clinical Review Guidelines and Review of Documentation for Medical Necessity
In evaluating a request for prior authorization of a prescription for a non-preferred Antipsychotic, the determination of whether the requested prescription is medically necessary will take into account the following:

1. For Abilify (aripiprazole) when prescribed for the treatment of Major Depressive Disorder (MDD) – Whether the recipient:
   a. Has a diagnosis of MDD
   AND
   b. Has a history of therapeutic failure, contraindication or intolerance to at least one agent in two of the following classes:
      i. Serotonin reuptake inhibitors (SSRIs)
      ii. Serotonin norepinephrine reuptake inhibitors (SNRIs)
      iii. Bupropion
   AND
   c. Is being prescribed aripiprazole as adjunctive treatment for MDD with therapeutic doses of an antidepressant
   AND
   d. Has a history of therapeutic failure, contraindication or intolerance to at least 150mg of quetiapine taken in combination with therapeutic doses of an antidepressant

2. For Invega - Whether the recipient has:
   a. A history of therapeutic failure of at least one (1) other preferred Antipsychotic;
   OR
   b. Active liver disease with elevated LFTs or is at risk for active liver disease

3. For all other non-preferred Antipsychotics - Whether the recipient:
a. Has a history of therapeutic failure, contraindication or intolerance to the preferred Antipsychotics;

AND

b. For Zyprexa Relprevv – Is being transitioned from oral Olanzapine to Zyprexa Relprevv

OR

c. Has a current history (within the past 90 days) of being prescribed the same non-preferred Antipsychotic

4. For a preferred or non-preferred Antipsychotic for a child under the age of 18 years – Whether the recipient

d. Has severe behavioral problems related to psychotic or neuro-developmental disorders such as seen in, but not limited to, the following diagnoses:

   i. Autism Spectrum Disorder, OR
   ii. Mental retardation, OR
   iii. Conduct Disorder, OR
   iv. Bipolar disease, OR
   v. Tic Disorder, including Tourette’s Syndrome, OR
   vi. Transient encephalopathy, OR
   vii. Schizophrenia

AND

e. Is being prescribed the medication by, or in consultation with a:
   i. Pediatric Neurologist, OR
   ii. Child and Adolescent Psychiatrist. OR
   iii. Child Development Pediatrician

AND

f. Has chart documented evidence of a comprehensive evaluation, including non-pharmacologic therapies such as, but not limited to, evidence based behavioral, cognitive, and family based therapies
AND

g. Has documented baseline monitoring of weight or body mass index (BMI), blood pressure, fasting glucose, fasting lipid panel, and Extrapyramidal Symptoms (EPS) using the Abnormal Involuntary Movement Scale (AIMS)

5. For therapeutic duplication of an Atypical Antipsychotic, whether:

a. The recipient is being titrated to, or tapered from, a drug in the same class

OR

b. Supporting peer reviewed literature or national treatment guidelines corroborate concomitant use of the medications being requested

6. In addition, if a prescription for either a preferred or non-preferred Antipsychotic is in a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in the Quantity Limits Chapter.

OR

7. Does not meet the clinical review guidelines listed above, but, in the professional judgment of the physician reviewer (a psychiatrist), the services are medically necessary to meet the medical needs of the recipient.

FOR RENEWALS OF PRESCRIPTIONS FOR PREFERRED and NON-PREFERRED ANTIPSYCHOTICS FOR CHILDREN UNDER 18 YEARS OF AGE: A request for prior authorization of a renewal of a prescription for an Antipsychotic for a child under 18 years of age that was previously approved will take into account whether the recipient:

1. Has documented improvement in target symptoms

AND

2. Has documented monitoring of weight or BMI quarterly

AND
3. Has documented monitoring of blood pressure, fasting glucose, fasting lipid panel, and EPS using AIMS after the first 3 months of therapy, and then annually

AND

4. Has a documented plan for taper/discontinuation of the Antipsychotic or rationale for continued use

OR

5. Does not meet the clinical review guidelines listed above, but in the professional judgment of the physician reviewer (a psychiatrist), the services are medically necessary to meet the medical needs of the recipient

C. Clinical Review Process

Except as noted below, prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above, to assess the medical necessity of the request for a prescription for an Antipsychotic. If the guidelines in Section B are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer (a psychiatrist) for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer (a psychiatrist), the services are medically necessary to meet the medical needs of the recipient.

NOTE: Approved requests for prior authorization of prescriptions for Symbyax will require the use of two (2) separate prescriptions for Fluoxetine and Zyprexa.

All requests for prior authorization of an antipsychotic medication for a child under 18 years of age will be automatically forwarded to a physician reviewer (a psychiatrist) for a medical necessity determination. The physician reviewer (a psychiatrist) will prior authorize the prescription when:

1. The guidelines in Section B. 3. are met,

OR

2. In the professional judgment of the physician reviewer (a psychiatrist), the services are medically necessary to meet the medical needs of the recipient

D. Dose and Duration of Therapy

February 13, 2012
(Replacing January 9, 2012)
Approvals of requests for prior authorization of prescriptions for an Antipsychotic for a child under 18 years of age will be limited as follows:

1. 3 months for an initial request
2. 12 months for a renewal of a previously approved request

References:

2. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes, Diabetes Care, 27:2, February 2004.